411 INNATE: immunotherapy during neoadjuvant therapy for rectal cancer to elucidate local and systemic therapeutic responses

福克斯 医学 结直肠癌 肿瘤科 放射治疗 化疗 癌症 内科学 新辅助治疗 临床试验 免疫疗法 外科 乳腺癌 奥沙利铂
作者
Nina N. Sanford,Eslam A. Elghonaimy,Adel Kardosh,Syed Mohammad Ali Kazmi,Javier Salgado Pogacnik,Xiaodong Yang,Robert Timmerman,Todd A. Aguilera
标识
DOI:10.1136/jitc-2021-sitc2021.411
摘要

Background

The relative risk of developing rectal cancer has quadrupled in young adults over the last 40 years and approximately 50% of patients develop recurrence within 3 years. Thus, there is a critical need for new approaches to improve survival but cancer Immunotherapy has had little impact on colorectal cancer. The anti-CD40 agonist immunotherapy is emerging and APX005M has shown promise in phase I and ongoing phase II trials. Anti-CD40 can stimulate both innate and adaptive immune responses and a greater response can be achieved combining anti-CD40 with radiation therapy (RT) in animal models. We developed the INNATE trial, a phase II randomized trial of neoadjuvant short course RT followed by chemotherapy with or without the addition of APX005M for rectal cancer (NCT04130854).

Methods

The INNATE trial is a multi-center, 58 patient, 3:2 randomization clinical trial, that adds APX005M to short course RT (SCRT) and subsequent FOLFOX chemotherapy prior to definitive radiation. Eligibility includes stage III and high risk stage II rectal cancer and candidates for standard neoadjuvant therapy and no contraindications for immunotherapy or radiation. Patients receive 5Gy x 5 fractions over five days and if randomized to experimental arm will receive APX005M on day 3 of radiation. After a two week break patients receive an optional endoscopy and biopsy followed by standard FOLFOX chemotherapy with APX005M infusion after disconnection of 5-FU chemotherapy pump. Study arm receives APX005M with 5 of 6 cycles of FOLFOX. After treatment patients undergo restating, endoscopy, and trans abdominal resection. The primary endpoint is pathologic complete response with the null estimated to be 20% and alternative 50% for a power of 0.8 and type 1 error of 0.1. Secondary endpoints include overall survival, toxicity analysis, and disease free survival. For correlative analysis, tissue is collected pre-treatment, two weeks after RT, and at surgery, then blood collected during treatment and at follow up.

Results

To date 16 patients have been randomized and initiated treatment. The treatment is well tolerated. Fiveteen patients received pre- and post-SCRT biopsies. The study team plans correlative analysis including single cell RNA sequencing, multiplex imunohistochemistry, and bulk sequencing. Preliminary data shows changes in the immune tumor microenvironment from patients treated as their own control and between SCRT versus SCRT + APX00M.

Conclusions

The INNATE trial shows feasibility of incorporating novel immunotherapies with an emerging standard of care incorporating short course RT. It serves as an important platform for scientific and clinical investigation.

Trial Registration

Clinicaltrials

gov: NCT04130854

Ethics Approval

The clinical trial has institutional review board approval at the University of Texas Southwestern, Oregon Health and Sciences University, Wake Forest, and Moffitt. All patients have provided informed consent.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐乐应助YYT采纳,获得10
刚刚
phoenix001发布了新的文献求助10
刚刚
羽翼完成签到,获得积分10
1秒前
唠叨的宝马完成签到,获得积分20
1秒前
量子星尘发布了新的文献求助30
1秒前
2秒前
2秒前
3秒前
顾难摧完成签到 ,获得积分10
3秒前
俭朴的小熊猫完成签到,获得积分10
3秒前
4秒前
4秒前
5秒前
www完成签到,获得积分10
5秒前
搜集达人应助lianqing采纳,获得10
5秒前
思源应助kiwiii采纳,获得10
5秒前
爆米花应助灌肠高手采纳,获得10
6秒前
jojo完成签到,获得积分10
6秒前
垃圾桶发布了新的文献求助10
7秒前
7秒前
Morty完成签到,获得积分10
7秒前
FashionBoy应助芝麻芝麻开门采纳,获得10
8秒前
Zxc发布了新的文献求助10
8秒前
8秒前
汤圆发布了新的文献求助10
8秒前
C女士发布了新的文献求助10
9秒前
科研通AI5应助daidaimumu采纳,获得10
10秒前
11秒前
冷艳的凉面完成签到,获得积分10
11秒前
黑色男孩发布了新的文献求助10
12秒前
林兰特发布了新的文献求助10
12秒前
14秒前
等光来发布了新的文献求助10
15秒前
Zxc完成签到,获得积分10
15秒前
Cici发布了新的文献求助10
16秒前
可爱的函函应助嘟嘟采纳,获得10
16秒前
自觉的傲薇应助云歇雨住采纳,获得10
16秒前
辛勤的孤容完成签到,获得积分10
17秒前
麻明英完成签到,获得积分10
17秒前
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance 500
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970004
求助须知:如何正确求助?哪些是违规求助? 3514701
关于积分的说明 11175468
捐赠科研通 3250051
什么是DOI,文献DOI怎么找? 1795187
邀请新用户注册赠送积分活动 875630
科研通“疑难数据库(出版商)”最低求助积分说明 804925